BIXT · XBRL financial data

Bioxytran financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (BIXT's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	316	544*	27	0*	51	34*	350	103	0*	2*	225	255
General and administrative	531	(628)*	447	441	154	399*	149	100	159	236*	214	189
Total operating expenses	985	1,007*	784	609	346	484*	515	224	496	607*	1,933	655
Operating income (loss)	(985)	(1,007)*	(784)	(609)	(346)	(484)*	(515)	(224)	(496)	(607)*	(1,933)	(655)
Interest expense	—	year only	26	20	18	20*	31	30	37	37*	36	36
Other income (expense)	(142)	—	—	—	(46)	—	—	—	—	—	—	—
Net income (loss)	(1,001)	(1,239)*	(800)	(662)	(392)	(512)*	(1,354)	35	(283)	(522)*	(2,069)	(620)
Earnings per share, basic USD per share	(0.01)	(0.01)*	0.00	0.00	0.00	—	(0.02)	0.00	0.00	(0.01)*	(0.02)	(0.01)
Earnings per share, diluted USD per share	(0.01)	(0.01)*	0.00	0.00	0.00	—	(0.02)	0.00	0.00	(0.01)*	(0.02)	(0.01)
Weighted average shares, basic thousands of shares	136,443	146,866*	162,808	176,606	126,391	—	88,840	88,840	88,992	100,604*	112,283	114,356
Weighted average shares, diluted thousands of shares	136,443	146,866*	162,808	176,606	126,391	—	88,840	88,840	88,992	100,604*	112,283	114,356

Fiscal quarters (BIXT's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	80	26	10	14	35	5	4	3	14	510	463	177
Total current assets	80	26	10	14	35	5	4	3	14	513	463	177
Total assets	189	139	126	129	159	139	136	148	156	659	615	333
Total current liabilities	2,333	3,244	1,116	1,229	1,244	1,931	2,844	2,783	3,061	3,250	5,010	5,275
Total deposits	—	—	—	—	—	—	—	—	—	112	188	—
Total liabilities	2,333	3,244	1,116	1,229	1,244	1,931	2,844	2,783	3,061	3,250	5,010	5,275
Accumulated deficit	(14,451)	(15,699)	(16,298)	(16,960)	(18,299)	(18,921)	(20,275)	(20,239)	(20,522)	(21,044)	(23,113)	(23,733)
Total stockholders' equity	—	—	—	—	—	(1,792)	(2,708)	(2,635)	—	(2,591)	(4,395)	(4,941)
Total liabilities and equity	189	139	126	129	159	139	136	148	156	659	615	333
Common shares outstanding (cover page) thousands of shares	144,642	166,493	174,962	177,956	85,783	88,882	88,992	88,992	99,104	113,362	114,195	114,695

Fiscal quarters (BIXT's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(1,001)	(1,239)*	(800)	(662)	(392)	(512)*	(1,354)	35	(283)	(522)*	(2,069)	(620)
Stock-based compensation	139	(69)*	168	11	8	—	—	—	—	—	—	—
Net cash from operating activities	(343)*	(93)*	(76)	(54)*	32*	42*	(167)	(81)*	(41)*	(237)*	(239)	(350)*
Net cash from investing activities	(13)*	(7)*	(6)	(1)*	(11)*	(10)*	(0)	(15)*	(2)*	(6)*	(9)	(9)*
Proceeds from issuing common stock	—	—	62	0*	2*	0*	—	—	—	year only	146	45*
Proceeds from issuing equity	390*	45*	4	59*	0*	0*	—	—	—	—	—	—
Net cash from financing activities	390*	45*	66	59*	0*	(62)*	167	95*	55*	739*	201	73*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Bioxytran	177	not reported	(350)*	114.7M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Artelo Biosciences	4,198	not reported	(5,033)*	4.6M	0.8 quarters	Q2 FY26 10-QJun 30, 2026
Raphael Pharmaceutical	1	not reported	0*	20.2M	—	Q2 FY26 10-QJun 30, 2026
Oncotelic Therapeutics	186	250	(92)*	457.5M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Alaunos Therapeutics	124	0	(300)*	2.5M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
TherapeuticsMD	9,189	not reported	not reported	11.6M	—	Q2 FY26 10-QJun 30, 2026
BioCardia	4,117	not reported	(1,735)*	15.1M	2.4 quarters	Q2 FY26 10-QJun 30, 2026
Traws Pharma	5,016	not reported	(7,504)*	15.4M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Mannatech	6,034	26,650	(792)*	1.9M	7.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.